Stress testing and non-invasive coronary angiography in patients with suspected coronary artery disease: time for a new paradigm by Arbab-Zadeh, Armin
Heart International 2012; volume 7:e2
Abstract
Diagnosis  and  management  of  coronary
artery disease represents major challenges to
our health care system, affecting millions of
patients each year. Until recently, the diagno-
sis  of  coronary  artery  disease  was  possible
only through cardiac catheterization and inva-
sive coronary angiography. To avoid the risks
of  an  invasive  procedure,  stress  testing  is
often employed for an initial assessment of
patients with suspected coronary artery dis-
ease,  serving  as  a  gatekeeper  for  cardiac
catheterization. With the emergence of non-
invasive coronary angiography, the question
arises if such a strategy is still sensible, par-
ticularly, in view of only a modest agreement
between stress testing results and the pres-
ence of coronary artery disease established by
cardiac catheterization. Much data in support
of  the  diagnostic  accuracy  and  prognostic
value of non-invasive coronary angiography by
computed  tomography  have  emerged  within
the last few years. These data challenge the
role of stress testing as the initial imaging
modality in patients with suspected coronary
artery disease. This article reviews the clinical
utility, limitations, as well as the hazards of
stress  testing  compared  with  non-invasive
coronary artery imaging by computed tomog-
raphy. Finally, the implications of this review
are discussed in relation to clinical practice.
Introduction
In  2008,  more  than  5  million  Americans
required emergency unit care for the evalua-
tion of chest pain and more than 16 million
Americans required a visit to the surgery for
chest pain evaluation.1 As a result, more than
10 million stress tests are being performed in
the US every year, as well as at least one mil-
lion diagnostic catheterizations.1,2The assess-
ment  of  patients  with  suspected  coronary
artery disease (CAD) places an enormous and
increasing burden on our health care system.3
Because  effective  treatment  is  available  to
reduce  the  risk  of  CAD  associated  adverse
events,  i.e.,  myocardial  infarction  and  acute
cardiac death, accurate and efficient diagnosis
of CAD is critical. In this review, the benefits
and risks of current and evolving strategies of
evaluating patients with suspected CAD will
be discussed.
Diagnosis of coronary artery
disease
The diagnosis of CAD begins with a dilem-
ma: while any definition of CAD includes a
description  of  coronary  atherosclerotic  dis-
ease, there is no consensus on how much ath-
erosclerosis is required to fulfill criteria for
CAD. Most seemingly healthy adult Americans
have  evidence  of  coronary  atherosclerosis,
with  approximately  10%  having  obstructive
disease.4,5 Thus, unlike other diseases, such
as cancer or infections, the diagnosis of CAD
is  typically  not  categorical,  i.e. present  or
absent. Rather, its significance is defined by
its quantity and extent. CAD is commonly used
to describe the condition of stenosed coronary
arteries  that  are  associated  with  symptoms,
often termed obstructive or significant CAD. In
the light of ample evidence that many myocar-
dial  infarctions  arise  from  coronary  athero-
sclerotic lesions that are only mildly stenotic,
the rationale for this terminology should be
questioned.6,7 The diagnosis of CAD is further
complicated when patients present with acute
symptoms. In patients with acute chest pain,
the diagnosis of CAD is made if an acute coro-
nary  syndrome  is  confirmed  by  biomarkers
and  electrocardiogram  (ECG),  even  in  the
presence of only mild CAD on cardiac catheter-
ization. Conversely, CAD is diagnosed in the
absence  of  an  acute  coronary  syndrome  if
angiography  shows  obstructive CAD.  These
ambiguities  represent  a  major  challenge  to
any  diagnostic  tool  which  aims  at  reliably
establishing a diagnosis. The introduction of
catheter-based coronary angiography in 1958
greatly  helped  the  understanding  and  the
treatment  of  CAD,  but  its  associated  risks
restricted its application to selected patients
with high pre-test probability of CAD. In most
cases, the initial approach to a patient with
suspected coronary artery disease has been to
perform myocardial stress testing which has
served as a gatekeeper for invasive coronary
angiography. 
Stress testing for diagnosis
and prognosis of coronary
artery disease
Stress testing has been used since the late
1920s  as  a  convenient,  non-invasive  way  to
assess  for  exercise  induced  myocardial
ischemia.8 Exercise increases myocardial oxy-
gen demand that may not be met in the pres-
ence of a coronary artery stenosis, leading to
myocardial ischemia with associated ST seg-
ment changes on the ECG, as well as symp-
toms. For patients unable to exercise, dobuta-
mine has been used to elicit an increase of
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cardiac  output,  and  thus  myocardial  oxygen
demand, similar to that resulting from exer-
cise.  Most  pharmacological  stress  testing  is
being  performed  today  using  vasodilators,
which do not apply cardiac stress per se, but
rather expose the inability of stenotic coronary
arteries to match the coronary blood flow of
unobstructed vessels, leading to relative differ-
ences in myocardial perfusion. The vast major-
ity of stress testing is being performed using
adjunctive imaging, which increases the sen-
sitivity  and  specificity  over  that  of  the  ECG
itself.9 Most commonly, this is nuclear perfu-
sion imaging, which uses the single-photon-
emission-computed-tomography  (SPECT)  as
the imaging modality of choice.
Accuracy of stress testing to
diagnose coronary artery disease
Numerous studies and meta-analyses report-
ed the diagnostic accuracy of stress testing to
identify patients with obstructive CAD, defined
as 50% diameter or more stenosis by quantita-
tive coronary angiography (QCA).10-13 Table 1
summarizes data for different types of stress
tests.  When  combined  with  imaging,  pooled
sensitivity for stress testing ranges from 80-
90% and specificity ranges from 70-80%; how-
ever,  several  caveats  need  to  be  considered.
These results are almost exclusively based on
single-center  experiences  that  are  typically
more accurate than centers in the community.
A recent European multicenter study assessing
the diagnostic accuracy of stress MRI  versus
SPECT found an area under the receiver oper-
ating characteristic (ROC) curve of only 0.67-
0.75 for SPECT; this is likely more representa-
tive  of  widespread  practice.14 Such  modest
diagnostic accuracy barely yields 70% sensitiv-
ity for equal specificity. Furthermore, diagnos-
tic accuracy studies using cardiac catheteriza-
tion as the gold standard are subject to referral
bias: only patients with sufficient suspicion for
obstructive CAD, typically based on a positive
non-invasive test, are being referred for inva-
sive angiography and meet inclusion criterion
for study enrollment. Accordingly, sensitivity is
inflated  while  specificity  is  decreased.13
Considering these limitations, it is unreason-
able to assume 80% or greater sensitivity and
specificity for stress testing to diagnose CAD in
clinical practice, even under the best of circum-
stances. Thus, at least 20% of stress tests with
imaging are either false positive or false nega-
tive  for  the  diagnosis  of  obstructive  CAD  in
patients. Not surprisingly, the rate of obstruc-
tive disease found on cardiac catheterization in
a large registry was found to be only 38% in
patients without prior history of CAD, despite
the  fact  that  non-invasive  testing  was  per-
formed in 89% of these patients prior to inva-
sive coronary angiography.15 Of note, a positive
non-invasive test only marginally increased the
rate  of  obstructive  disease  in  these  patients
from 36 to 41%.
Prognostic value of stress testing
Similar to the diagnostic data, there have
been numerous studies, notably almost exclu-
sively single-center studies, reporting patient
outcome  after  stress  testing.16-19 In  general,
two  important  variables  must  be  considered
when reviewing the outcome after any test: the
type of outcome and the morbidity in the study
population. Total mortality is the easiest and
most reliable outcome measure to obtain, but
it is substantially influenced by the morbidity
in the study population. Furthermore, it does
not adequately inform on the outcome that is
associated with the diagnosis to be tested, i.e.
coronary artery disease. Depending on the co-
morbidity in the patient population, there may
be substantial mortality attributed to non-car-
diac  (or  more  specifically,  to  non-coronary
artery disease) related deaths, which is still to
be attributed to events after testing. Therefore,
myocardial  infarction  and  cardiac  death,
though more vulnerable to attribution bias, are
the  preferred  outcome  measurements  after
testing for coronary artery disease. 
Unfortunately, outcome studies after stress
testing vary widely in their end points, hinder-
ing pooling of data. Table 2 summarizes avail-
able data for myocardial infarction and cardiac
death occurring after stress testing. The most
robust data are available for nuclear stress per-
fusion studies, whereas exercise treadmill test-
ing data are difficult to extract due to end point
variability. With a 0.65% annualized event rate,
myocardial infarction and cardiac death is fairly
low for normal exercise SPECT; on the other
hand, 1.78% is rather substantial for a normal
pharmacological SPECT.16 When extrapolating
the latter event rate to ten years, almost 18%
suffer  myocardial  infarction  or  cardiac  death
after a normal pharmacological nuclear stress
test, which is a risk level bordering on that of
established  CAD.  Because  at  least  40%  of
nuclear stress tests are being performed with
pharmacological stress, such a scenario applies
to millions of patients each year.16 Bangalore et
al. risk stratified patients in the same patient
cohort and found annualized event rates that
more than quadrupled (0.3% vs1.4%) in moder-
ate/ high versus low risk patients with normal
stress echocardiograms.19 These very different
event rates for normal exercise versus normal
pharmacological  stress  tests  are  generally
attributed to greater co-morbidity and the asso-
ciated  atherosclerotic  disease  burden  within
the pharmacological stress group. Thus, when
assessing prognosis for patients based on stress
testing results, it is important to consider the
patient’s co-morbidity and risk categorization. A
normal stress test in a patient with significant
co-morbidity by no means indicates a benign
prognosis.  An  important  limitation  of  stress
testing is its inability to detect non-obstructive
coronary atherosclerotic plaque, which is capa-
ble  of  triggering  events.  An  overall  (exercise
and pharmacological stress testing combined)
event rate of approximately 1% for myocardial
infarction  and  cardiac  death  after  a  normal
Table 1. Accuracy of stress testing for detecting obstructive coronary artery disease as
defined by quantitative coronary angiography.
Test N Sensitivity Specificity
Exercise treadmill test 24,074 68 77
Exercise nuclear MPI 2,360 88 70
Vasodilator nuclear MPI 4,582 89 77
Dobutamine nuclear MPI 1,359 84 79
Exercise echocardiography 2,637 85 77
Dobutamine echocardiography 6,881 81 82
MPI, myocardial perfusion imaging. 
Table 2. Annualized rates of myocardial infarction and cardiac death at follow up accord-
ing to stress testing results. 
N Median MI/Cardiac MI/Cardiac
Test follow up death with death with
(months) normal test abnormal test
Exercise treadmill test 1,647 30 0.80* 2.00°
Exercise Nuclear MPI 9,930 20 0.65 4.30
Pharmacologic Nuclear MPI 4,988 22 1.78 9.98
Exercise Echocardiography 4,347 36 0.50 2.06
Dobutamine Echocardiography 1,930 32 1.13 4.33
MI, myocardial infarction; MPI, myocardial perfusion imaging. *indicates low risk Duke treadmill score; °indicates high risk Duke treadmill
score. Review
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stress  test,  while  generally  considered  a  low
event rate, has substantial implications because
of the large numbers of patients affected. Given
that at least 10 million patients undergo stress
testing in the US annualy, with approximately
70% reported normal, up to 70,000 patients suf-
fer myocardial infarction or cardiac death each
year after a normal stress test. 
Non-invasive coronary artery
imaging for diagnosis and
prognosis of coronary artery
disease
Non-invasive imaging of the coronary arter-
ies has been extremely challenging because of
the high demands on temporal and spatial res-
olution  for  imaging,  which  allows  detailed
depiction of the rather small coronary arteries.
Both whole heart magnetic resonance imaging
(MRI) and multidetector computed tomography
angiography (CTA) have emerged as non-inva-
sive  imaging  tools  that  have  significantly
advanced  the  field  of  non-invasive  coronary
imaging. Current generation MRI, 1.5 Tesla or
greater,  yields  good  temporal  resolution
(approximately 20-40 ms) compared to invasive
coronary angiography (10-20 ms) but its spatial
resolution is far inferior (1.5 vs 0.15 mm).20 CT
angiography, on the other hand, has fairly good
spatial resolution (0.35-0.60 mm), but its tem-
poral resolution varies widely, typically between
80-180  ms.  This  requires  beta  blockers  to
lengthen diastasis for motion free image recon-
struction. Because of its better spatial resolu-
tion and speed of image acquisition, as well as
its wide spread availability, CT angiography has
come to the forefront as the more accurate and
robust method for non-invasive coronary imag-
ing, despite the disadvantage of requiring X-ray
radiation.21 Furthermore,  CT  technology  has
evolved  very  rapidly  over  the  past  few  years
with major improvements in temporal resolu-
tion,  with  radiation  doses  much  lower  than
conventional  CT  imaging.22 Despite  these
advancements, however, beta blocker applica-
tion prior to scanning is still required in the
vast  majority  of  cases.  Because  of  the  more
prominent role of CT for non-invasive coronary
artery imaging, compared to other modalities,
this review will focus on CT coronary angiogra-
phy (CTA) for this purpose.
Computed tomography
angiography diagnostic accuracy
for detecting obstructive coronary
artery disease
Similar  to  stress  testing,  there  have  been
numerous  single-center  studies  documenting
the  diagnostic  accuracy  of  CTA  compared  to
QCA for stable patients with suspected CAD.23-25
Meta-analyses reveal exceedingly high diagnos-
tic accuracy to identify CAD in patients with
pooled AUC ranging between 0.97-0.99, depend-
ing on whether patients with known CAD were
included  or  not.  Pooled  sensitivity  ranges
between 98-99%; specificity ranges between 82-
89% in meta-analyses (Figure 1).23,24 Similar to
the data on stress testing, however, many of the
studies on CTA are subject to referral bias, sug-
gesting that true sensitivity is likely lower, while
specificity  is  higher  in  less  selected  popula-
tions. There have also been several multicenter
studies that yielded AUCs between 0.93 and 0.96
for 64-slice detector technology among patients
with a wide range of disease prevalence, coro-
nary  calcification,  and  image  quality.26-28
Predictive values, while frequently referenced
in the context of diagnostic accuracy, are highly
dependent  on  the  disease  prevalence  in  the
study  population  and  should,  therefore,  be
viewed accordingly.26 Positive predictive values
are generally lower and negative predictive val-
ues are higher in low-risk populations and vice
versa. Despite some criticism on the positive
predictive values by CTA, single-center studies
with  very  different  study  populations  yielded
median positive and negative predictive values
of  93%  and  100%  in  patients,  respectively.23
When pooling the data from the three major
multicenter studies (n=961) with a higher dis-
ease prevalence (53%) than typically encoun-
tered in symptomatic patients without known
CAD, positive and negative predictive values are
85% and 92%, respectively.
It is important to note that the diagnostic
data available for CTA are at least equivalent
to  those  for  stress  testing  with  regards  to
number of subjects, length of follow up, char-
acteristics of patient populations, gold stan-
dards used, and end points. In fact, diagnostic
accuracy data are more robust for CTA than
for stress testing, as the former includes sev-
eral multicenter studies. Thus, data sets for
CTA and stress testing are sufficiently con-
gruent  to  allow  comparison.  Furthermore,
data from seven clinical studies, comparing
CTA directly to stress testing for the diagnosis
of  obstructive  CAD  are  currently  available
(Table 3).29-35 Pooled sensitivity and specifici-
ty for 483 patients were 96% and 88% for CTA,
but only 66% and 69% for nuclear stress test-
ing, respectively. These disappointing results
for nuclear stress testing are consistent with
data from an independent core laboratory for
225  patients  from  18  centers  evaluating
SPECT in comparison with stress MRI.14 On
the other hand, results for CTA are in agree-
ment with those obtained in single and multi-
center  studies.  Hence,  data  from  studies
directly  comparing  CTA  with  stress  testing
support the results from diagnostic accuracy
studies performed separately for these modal-
ities, confirming substantially superior diag-
nostic performance for CTA. The remarkable
consistency  of  these  study  results  and  the
magnitude of differences in diagnostic per-
formance  between  CTA  and  stress  testing
allow us to have great confidence in this con-
clusion.
Figure 1. Sensitivity, specificity, positive predictive value (PPV), negative predictive value
(NPV) of computed tomography angiography for detecting 50% stenosis or over by quan-
titative coronary angiography based on a meta-analysis of 3,674 symptomatic patients
without history of coronary artery disease enrolled in 28 studies.24Review
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Prognostic value of computed
tomography angiography
Three recent meta-analyses and one large
registry  document  patient  outcomes  for
patients with suspected CAD who underwent
CTA.36-39 The number of patients included in
these  investigations,  ranging  from  5,000-
23,000, is comparable to data available from
the nuclear medicine literature. In addition,
the patient populations (patients referred to
evaluate chest pain) and the median follow up
(1-2 years) are similar to the nuclear medicine
literature.  These  data,  therefore,  are  quite
applicable for comparison among these modal-
ities. On the other hand, most of the prognos-
tic data available for CTA only report total mor-
tality  as  outcome,  while  few  provide  break-
downs  of  cardiac  mortality  and  myocardial
infarction. Since total mortality is substantial-
ly influenced by the co-morbidity and charac-
teristics of the study population, comparisons
of  total  mortality  between  different  popula-
tions  have  to  be  interpreted  with  caution.
Unfortunately, several meta-analyses included
studies with both cardiac and total mortality
without adequately differentiating the results.
Furthermore, results for CTA were categorized
into normal, non-obstructive, and obstructive
CAD, as opposed to SPECT data which were
reported as normal versus abnormal. 
Overall,  a  CTA  with  obstructive  CAD  has
similar  event  rates  to  an  abnormal  SPECT:
approximately 4% annualized rate of death or
myocardial infarction (Figure 2). Conversely, a
normal  CTA  has  lower  rates  of  death  and
myocardial  infarction  than  a  normal  SPEC,
which is a key finding. Specifically, in patients
with normal CTA, total mortality is similar to a
reference population (0.15% annualized total
mortality) in a recent meta-analysis.36 For a
subset of 1,681 patients with a normal CTA,
information on cardiac mortality is also avail-
able.36,40 Among these, notably, there was no
case of CAD related mortality (one patient died
of a myosarcoma which was counted as cardiac
mortality).40 Equally important, there was no
case of myocardial infarction in those followed
after  a  normal  CTA.36 Rates  for  myocardial
infarction and death were approximately 1%
per year for non-obstructive CAD equivalent to
event  rates  with  a  normal  SPECT,  which  is
unable to detect non-obstructive CAD.
A recently published large international reg-
istry,  consisting  mainly  of  low-intermediate
risk patients, confirmed very low total mortali-
ty in patients with normal CTA, but informa-
tion for cardiac mortality or myocardial infarc-
tion is not available from these data.38 Only
one  study  compared  patient  outcomes  from
CTA to SPECT in the same patient cohort41 and
after  a  median  follow  up  of  672  days,  CTA
analysis  resulted  in  incremental  prognostic
value  for  total  mortality  over  SPECT  in  517
patients. Importantly, the annualized mortality
rate  was  more  than  three  times  greater  in
patients with normal SPECT compared to those
with normal CTA (1.1 vs 0.3%), and because no
breakdown of events was provided, it remained
unclear if any CAD related events occurred in
patients  after  a  normal  CTA.  Another  study
compared  outcome  data  after  CTA  (n=693)
with SPECT (n=3,067) using a matched cohort
comparison  study  design,  which  concluded
similar prognostic performance.42 No separate
analysis was performed for patients with a nor-
mal CTA, i.e. with no evidence of CAD, limiting
the results. 
For  patients  presenting  with  acute  symp-
toms,  few  follow-up  data  are  available.  The
ROMICAT  study,  similar  to  studies  in  stable
patients, revealed no major adverse cardiovas-
cular events in 183 patients two years after
presenting with acute chest pain and normal
ECG/cardiac  makers.43 Conversely,  185
patients  with  non-obstructive  or  obstructive
CAD  had  annualized  event  rates  of  2.3  and
15.2%, respectively. A multicenter study ran-
domized  low-risk  patients  with  acute  chest
pain to a CTA vs SPECT guided management,
with  time  to  diagnosis  as  the  primary  end
point.44 As a result, CTA led to a more rapid
diagnosis  while  other  outcome  was  similar
within the groups. Of note, myocardial infarc-
tion occurred in 0.3% among patients found to
have normal or mild CAD by CTA, versus 1.5%
in  patients  with  low-risk  SPECT,  after  six
months (P=0.11); no analysis was provided for
patients with normal CTA, i.e. the absence of
any CAD.
Overall, CTA, using simple categorization of
no CAD, non-obstructive CAD, and obstructive
CAD, conveys risk stratification that appears
superior  to  that  obtained  by  stress  testing
because it identifies a sizable subgroup (20-
30%) of patients who are at exceedingly low
risk of adverse events. In fact, available data
suggest that there is a total absence of CAD
related events in patients with normal CTA for
at least two years after testing.36,40,45 It is con-
ceivable that other CTA characteristics, such
as individual plaque burden and composition,
Table 3. Direct comparison of computed tomography angiography vs single-photon-
emission-computed-tomography for detecting ≥50% coronary artery stenoses as defined
by quantitative coronary angiography.
Study N CTA CTA SPECT SPECT
sensitivity specificity sensitivity specificity
Budoff et al.30 30 95 89 81 78
Schuijf et al.32 58 100 81 70 58
Gaemperli et al.31 78 94 100 53 83
Gallagher et al.29 85 86 92 71 90
Budoff et al.35 48 92 78 76 57
Arbab-Zadeh et al.34 62 95 100 86 45
Hamirani et al.33 122 99 74 56 39
Pooled results 483 96 88 66 69
CTA, computed tomography angiography; SPECT, single-photon-emission-computed-tomography. 
Figure 2. Annualized rates of death or myocardial infarction after computed tomography
angiography  according  to  study  results  based  on  a  meta-analysis  of  9,592  patients
enrolled in 18 studies.36 CAD, coronary artery disease.Review
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total  atherosclerotic  plaque  burden  etc.,  fur-
ther  improve  predictive  power.  For  example,
Ostrom et al. followed 2,538 individuals for a
mean of 6.5 years after CTA and found an area
under the curve of 0.89, predicting total (not
cardiac!) mortality, based on simple cardiac CT
categories of normal arteries, non-obstructive,
and obstructive coronary artery disease, com-
bined with a calcium score and traditional risk
factors.46
Anatomy versus physiology: what
matters most for patients with
suspected coronary artery disease?
The  key  objective  in  the  evaluation  and
management of patients with suspected CAD
is the prevention/risk reduction of acute coro-
nary events, i.e. myocardial infarction and car-
diac death. The pathophysiology of such acute
coronary events has been extensively studied,
and central to this concept is the alteration of
coronary  atherosclerotic  plaque,  e.g. erosion
and rupture, in the presence of a thrombosis
conducive  state.47 Numerous  studies  estab-
lished  a  strong,  consistent  relationship
between the presence and extent of coronary
atherosclerotic disease and the occurrence of
acute coronary events. Most impressively, an
analysis of more than 25,000 patients showed
an increase in mortality even for a small incre-
ment in coronary calcium score, a surrogate of
coronary  atherosclerotic  burden.48 A  larger
coronary  atherosclerotic  plaque  burden  is
associated with more frequent plaque ruptures
or erosions increasing the probability that one
of them coincides with a thrombosis conducive
state triggering an event.47
While  the  relationship  between  the  pres-
ence and extent of CAD and coronary events is
well established, the role of inducible myocar-
dial  ischemia  for  predicting  acute  events  is
less certain. Although many studies suggest a
greater  number  of  acute  coronary  events  in
patients with inducible perfusion abnormali-
ties by stress testing, compared to those with-
out,  it  remains  unclear  if  stress  induced
ischemia  provides  independent  prognostic
value, or if inducible ischemia simply repre-
sents a surrogate for the severity of underlying
CAD. Several observations suggest the latter.
As outlined above, meta-analyses of thousands
of patients revealed a relatively low but consis-
tent  number  of  acute  coronary  events  in
patients  despite  normal  stress  test  findings,
documenting that the absence of myocardial
ischemia does not preclude acute events soon
after testing. Furthermore, the COURAGE and
several other randomized trials have failed to
demonstrate a reduction in myocardial infarc-
tion and death in patients with chronic angina
who  underwent  revascularization  despite
reduced ischemic burden on stress testing.49 A
sub-analysis of the COURAGE trial suggested a
worse outcome in patients with large residual
ischemic burden compared to those without;
however, these results lost statistical signifi-
cance after risk adjustments, even before con-
sidering the severity of the underlying CAD. 
In studies employing both calcium scanning
and stress testing in the same patients, the
presence of calcified coronary atherosclerotic
plaque conveyed increased risk for subsequent
cardiac events in patients, even with a normal
stress perfusion study.50 Conversely, long-term
follow up of patients with chest pain and nor-
mal coronary arteries by invasive angiography
revealed a total annualized mortality equiva-
lent to a normal reference population despite
the presence of ischemia on stress testing in
some.51 Importantly, follow up of patients with
chest  pain  and  abnormal  stress  test  results
were found to have repeated hospitalizations
for chest pain evaluation, but there were no
acute coronary events.52Hence, while coronary
atherosclerosis clearly is integral to the patho-
physiology of acute coronary events, inducible
ischemia has not been shown to be of prognos-
tic importance for myocardial infarction and
death that is independent from the presence
and  extent  of  coronary  artery  disease.  It
remains to be seen if the presence and severi-
ty of inducible myocardial ischemia can pro-
vide information that is incremental to a com-
prehensive assessment of coronary anatomy.
Risk - benefit considerations of
stress testing versus computed
tomography angiography
Potential benefits derived from
imaging
Any imaging to procedure should be of suffi-
cient benefit to a patient, helping to outweigh
potential risks and side effects. In the case of
cardiac  imaging  for  CAD,  the  benefit  is
assumed because it establishes the diagnosis
of CAD, which may then prompt treatment and
reduce the risk of subsequent events. In con-
trast, ruling out CAD may alleviate the need for
medications and further testing, lowering the
risk from drug interactions and adverse effects.
Since there are no prospective, controlled stud-
ies documenting outcome benefit for patients
undergoing imaging, it remains unclear if all or
most  patients  benefit,  or  if  the  risk-benefit
ratio is unfavorable for many. A key problem for
testing  these  hypotheses  is  that  there  is  no
adequate  control.  Not  testing  appears  to  be
impractical and not a valid alternative in most
cases. Demonstrating superiority of a specific
testing  strategy  over  another,  on  the  other
hand, requires a very large number of partici-
pants and/or extensive follow up, which may be
cost prohibitive and impractical. 
To come to some reasonable estimates with
regards to the benefits of diagnosing CAD, the
following assumptions are made: approximate-
ly 20% of relative risk reduction for myocardial
infarction and death are secondary to preven-
tative measures (including risk factor interdic-
tion, pharmacotherapy, and revascularization);
approximately 30% of stress tests are abnor-
mal; sensitivity and specificity are (optimisti-
cally)  80%  for  stress  testing;  there  is  a  4%
annualized event risk for untreated patients.
Accordingly, 24% of all patients will have a cor-
rect diagnosis of obstructive CAD, resulting in
an  absolute  annualized  reduction  of  0.192%
(0.960 minus 0.768%) for myocardial infarc-
tion and death, applied to all patients undergo-
ing stress testing. Thus, of 521 patients under-
going stress testing for suspected CAD, there
would be one myocardial infarction or death
prevented per year as a result of testing. 
Because of the superior diagnostic accuracy
for  CTA,  its  benefit  is  somewhat  greater.
Assuming a conservative 90% sensitivity and
specificity, 27% of patients will benefit from
the correct diagnosis of obstructive CAD. The
associated annualized 20% relative reduction
in myocardial infarction and death will result
in a 0.216% absolute risk reduction each year
for  myocardial  infarction  and  death  for  all
patients  undergoing  CTA  testing.  In  other
words,  463  patients  would  need  to  undergo
testing for one myocardial infarction or death
per year to be prevented. In addition to diag-
nosing obstructive disease, CTA is capable of
diagnosing non-obstructive disease. Assuming
similar  risk  reductions  when  treated  and  a
similar normal/abnormal study ratio for stress
testing  with  50%  of  normal studies  having
non-obstructive CAD,36 an annular event rate
of  approximately  1%,  with  an  additional
absolute  reduction  in  annular  event  rate  of
0.07%, would be applied to all patients under-
going  CTA,  for  a  total  of  a  0.286%  absolute
reduction in annular myocardial infarction and
death (for every 350 patients undergoing CTA
for evaluation for CAD one hard event is pre-
vented per year). Furthermore, CTA has anoth-
er very important advantage over stress testing
in  its  capability  to  exclude  any  disease  as
opposed  to  excluding  only  obstructive  CAD.
Since  a  normal  CTA  is  associated  with  the
absence  of  myocardial  infarction  and  CAD
related deaths for at least two years after test-
ing,36,40,45 patients are very unlikely to benefit
from further short-term testing and CAD tar-
geted pharmacotherapy, which will reduce risk
of adverse events associated with these meas-
ures. Drawing from long-term follow-up data
after a normal CTA which, however, provided
only information on total mortality, survival is
100%  after  five  years  with  possible  longer
event free survival if cardiac mortality is con-
sidered.46 Thus,  the  data  currently  available
suggest that the warranty period for a normalReview
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CTA in properly selected patients is at least 2-5
years,  considering  the  absence  of  any  hard
events or mortality, but could possibly be much
longer. The extent of this potentially enormous
impact on the testing and treatment strategies
for millions of patients is difficult to estimate
at the present time, but it must be viewed as
extremely  positive.  Other  important  benefits
from  testing,  diagnosis,  and  treatment,  e.g.
symptom relief, quality of life, etc., must also
be considered, even though these benefits are
currently more difficult to estimate.
Direct and indirect risks of stress
testing
Risks from stress testing vary substantially,
and  these  risks  depend  on  the  form  of  the
stress and the imaging combined. In its most
basic  form,  the  risk  from  exercise  treadmill
testing is confined to strenuous exercise that
is associated with approximately 0.04% risk of
myocardial infarction or death.53 Fewer data
are available for dobutamine instead of exer-
cise stress, with reported rates of myocardial
infarction or death of 0.025%.54,55 Myocardial
infarction or death associated with vasodilator
stress appears  to  be  similarly  rare,  with  an
approximate  rate  of  0.028%.56 However,  if
nuclear perfusion imaging is performed, the
radiation dose must be added to the risk pro-
file. A typical radiation dose for a sestamibi
rest-stress  protocol  encompasses  11  mSv,
whereas a dual isotope protocol involving thal-
lium yields a dose of 24 mSv.57 Adopting the
guidelines  set  by  BEIR  VII  at  the  National
Academy of Sciences, a 0.1% risk of cancer is
assumed for any 10 mSv dose.58 Accordingly, a
reasonable assumption of risk for myocardial
infarction, cancer, or death results from stress
testing that ranges from 0.025% with dobuta-
mine echocardiography, to 0.28% for an exer-
cise nuclear perfusion study using thallium. 
In addition to the direct risks from stress
testing, there are indirect risks, i.e. adverse
effects from false positive or false negative test
results. Since there is a 70% normal testing
result and an optimistic 80% sensitivity and
specificity, approximately 1.4 million patients
in the US will have a false positive or negative
stress test result every year. Assuming that one
fourth will undergo cardiac catheterization for
a false positive result with a major complica-
tion rate of 1.7%, including 0.23% for myocar-
dial  infarction,  stroke,  or  death,59 5,950
patients every year (0.06% of all patients) will
suffer major complications, and 805 patients
(0.008%) will suffer life threatening complica-
tions  from  an  invasive  procedure  that  was
prompted by a false positive stress test. Even
more important, however, is the effect of false
negative testing results. These results can be
divided into two categories: a) false negative
test result for obstructive CAD; and b) the cat-
egorical  inability  of  stress  testing  to  detect
non-obstructive CAD. At least 20% of patients
will have false negative results for obstructive
CAD, and an annualized 0.8% excess risk of
myocardial infarction and death must be con-
sidered using the same assumptions as made
above.  This  adds  a  0.048%  annualized  or  a
0.48% 10-year risk of myocardial infarction and
death when applied to the entire stress testing
population.  As  70%  of  patients  with  normal
stress testing results have on average a 1%
event rate because of undetected non-obstruc-
tive disease, an additional annualized excess
risk of 0.14% (1.4% 10-year risk) for the entire
group applies. 
It  becomes  apparent,  therefore,  that  the
adverse effects from false positive or false neg-
ative test results for CAD have a larger impact
than the risks associated with the tests them-
selves.  By  accruing  all  excessive  risks  from
stress  testing  for  a  10-year  follow-up  period
(assuming it fulfills requirements for cancer
development  from  radiation),  an  excessive
risk  of  2%  for  myocardial  infarction,  stroke,
cancer, or death from stress testing is realistic.
Conversely, considering a 1.9% absolute risk
reduction  for  myocardial  infarction  or  death
over  ten  years,  for  the  correct  diagnosis  of
obstructive  CAD,  the  risk-benefit  ratio  for
stress testing is not convincing. 
Direct and indirect risks of
computed tomography coronary
angiography
Direct risks from CTA are confined to con-
trast application, beta blocker application, and
radiation dose. Risk from myocardial infarc-
tion or death associated with contrast applica-
tion is exceedingly low, and was 0.003% in a
series of over 29,000 patients undergoing CT
angiography.60 Risk from beta blocker applica-
tion in preparation for a CTA has been studied
only in a few case series, which suggests an
exceedingly low risk for severe adverse events
with no reported cases of myocardial infarction
or  death.61 Radiation  doses  from  a  coronary
CTA vary drastically with the image acquisition
protocol and technology used. More recently, a
dramatic  decrease  in  radiation  doses,  from
approximately 20 to less than 1 mSv in some
studies,  has  become  noticeable.22 The
Protection I study surveyed the radiation doses
in clinical practice at 50 worldwide centers and
found a median dose of 12 mSv with a wide
range of median doses among the participat-
ing centers.62 However, this study reflects the
practice pattern from 2007, and likely repre-
sents  an  overestimation  of  doses  from  CTA
compared to current practice today. Growing
use  of  prospective  scan  triggering,  low  tube
voltage settings, and novel image reconstruc-
tion techniques have resulted in an average
estimated dose of 2.7 mSv (95% CI 2.2-3.2) in
960 patients assessed in a recent meta-analy-
sis of 16 studies.25 Even when considering dif-
ferences in image acquisition in the communi-
ty, it is reasonable to assume that the majority
of laboratories yield effective doses from CTA
that on average do not currently exceed 5 mSv,
and have a strong trend for further reductions.
Considering BEIR VII guidelines, such doses
are  associated  with  an  approximately  0.05%
excess risk of cancer later in life.58
As  with  stress  testing,  indirect  risks  are
more relevant than direct risks. When applying
the same assumptions for stress testing, but
then adjusting for the superior diagnostic accu-
racy by CT, approximately 10% of patients will
have false positive results for obstructive CAD.
Again, assuming that one fourth will undergo
cardiac  catheterization  with  the  associated
event rate of 0.23% for myocardial infarction,
stroke,  or  death,  an  estimated  0.0058%  of
patients undergoing CTA will fall into this cate-
gory, or 0.058% over ten years. Furthermore,
approximately 10% of patients will have false
negative results for obstructive CAD (with an
annualized 0.02% or 0.2% 10-year excess risk of
myocardial infarction and death) when applied
to the entire testing population. CTA has the
ability to detect non-obstructive disease, but its
impact is unclear because of an inadequate ref-
erence standard. Assuming a 10% false nega-
tive rate and an event rate of 1% in this group,
an  excess  risk  of  0.014%  likely  applies.  The
cumulative 10-year excess risk of myocardial
infarction, stroke, cancer, or death of 0.451% is
outweighed by a 2.9% event reduction for cor-
rect diagnoses, which is a favorable risk-bene-
fit ratio.
One factor that was not discussed in this
context is the need for follow up imaging for
incidental  non-cardiac  findings  seen  on  CT
imaging. Depending on the study population,
significant non-cardiac findings that require
follow up or a change in management occur in
1-30% of cases.63,64 For a rather low risk popu-
lation encountered in patients without known
CAD, this rate is approximately 5%.64 It is diffi-
cult to ascertain if incidental findings on CT
imaging have to be regarded as an advantage
or a limitation. Although there are limited data
available about radiation exposure and toxicity
from follow-up imaging, recent data suggest
that screening patients for lung cancer, using
low  dose  CT,  reduces  mortality.65 It  remains
unclear if this benefit also applies to patients
with  a  much  lower  risk  for  lung  cancer.
Likewise,  it  is  unclear  if  detecting  other
pathologies,  such  as  pulmonary  embolism,
pneumonia,  or  aortic  aneurysm/dissection,
outweighs  the  risk  from  radiation  and  con-
trast. Given the low dose and contrast require-
ments  for  contemporary  cardiac  CT  and  the
seriousness of detected conditions, a favorable
risk-benefit ratio must be regarded as likely.Review
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Cost considerations
Direct costs for SPECT and CTA are similar.
Medicare reimbursement for exercise SPECT
averages $500 for technical and $200 for pro-
fessional  services  versus $550  and  $180  for
CTA, respectively.66 Several studies addressed
cost effectiveness for CTA versusSPECT. Min et
al. examined the use of CTA as a first-line test
for patients with suspected CAD in comparison
with  SPECT  and  found  CTA  was  more  cost
effective even when not considering a detailed
risk-benefit analysis as outlined above.66 In a
randomized controlled trial, CTA was more cost
effective  also  in  patients  with  acute  chest
pain.44 It is conceivable that the benefit of CTA
is even more apparent if costs from adverse
effects are fully considered. Ironically, relative-
ly low reimbursement for CTA has been instru-
mental in limiting its wide spread application.
Equipment and overhead costs are higher for
CTA than for SPECT, and practices struggle to
recover  their  expenses  for  CTA,  particularly
since  study  interpretation  is  substantially
more  time  consuming  compared  to  SPECT.
Thus,  economic  considerations  hinder  the
application  of  imaging  tools  with  superior
diagnostic accuracy for many patients.
Conclusions and implications
for clinical management
There is remarkably little prospective, ran-
domized data that steer image guided clinical
management toward patient outcomes.67 Some
studies  addressed  the  question  of  medical
treatment versus revascularization, based on
SPECT imaging findings in patients with CAD.
But despite widespread acceptance in the med-
ical community, these investigations were lim-
ited  by  observational  and/or  retrospective
designs.68,69 Stress testing has been used for
decades to obtain a reasonable estimate for the
likelihood of obstructive coronary artery dis-
ease  and  its  associated  cardiac  event  risk.
Because of a lack of valid alternatives, such an
approach was never prospectively investigated.
Since the emergence of non-invasive imaging,
there have been several meta-analyses docu-
menting both greater diagnostic accuracy and
prognostic information for CTA, compared to
stress testing in patients with suspected coro-
nary  artery  disease.  Despite  equal  or  lesser
toxicity and cost for CT coronary angiography,
when comparing CTA to stress testing, there
has been a reluctance on the part of the med-
ical community to embrace CT as the primary
diagnostic tool for the assessment of patients
with suspected coronary artery disease. Given
the abundance of clinical data, it is time to
accept CTA as an established imaging modali-
ty for the assessment of patients with suspect-
ed CAD.70
While there is conclusive evidence that the
presence and extent of CAD strongly relates to
cardiac event risk, it is still unclear if the risk
from myocardial ischemia, as detected by stress
testing,  is  merely  related  to  the  underlying
CAD, or if there is an independent risk associ-
ated with ischemia. Nonetheless, health care
experts  demand  large  scale  studies  to  prove
better outcome for patients assessed by CTA
compared  to  alternative  management,  even
though no such evidence exists for stress test-
ing or other cardiac imaging.67 The outlined
estimates  for  outcome  benefits  from  stress
testing and CTA reveal that much larger patient
numbers than commonly enrolled are neces-
sary to show outcome benefit, given the low
number of events and relatively small reduction
in risk. However, in view of the many millions
of patients undergoing testing for CAD, these
differences are indeed relevant for the outcome
of thousands of patients each year.
When given the choice between stress test-
ing  and  CTA  for  an  initial  assessment  of
patients  with  suspected  coronary  artery  dis-
ease, there is evidence to support the superior-
ity of an assessment using CTA, and it appears
prudent to implement CTA as the preferred tool
pending evidence to the contrary. Based on the
data available, it is plausible that thousands of
patients suffer myocardial infarction and car-
diac death each year after normal stress testing
results  that  could  have  been  identified  and
treated if CTA was employed instead of stress
testing. Therefore, the burden of proof must be
on stress testing and not on CTA to deliver evi-
dence of this well based hypothesis. Such evi-
dence  may  not  be  generated  any  time  soon
because  of  the  inflated  cost  involved.  Even
large scale studies, such as the PROMISE study,
are unlikely to demonstrate differences in hard
end points unless longer follow up is imple-
mented. Furthermore, the diagnostic and prog-
nostic advantage of CTA over stress testing is
so  clearly  evident  that  it  appears  prudent  to
invest research dollars into clinical studies that
inform  clinicians  of  the  best  management
strategies based on test results, rather than on
comparison studies among imaging modalities.
Until such data are available, we are left with
our best judgment to apply imaging results in
clinical practice. A suggested algorithm for ini-
tial testing in patients with suspected CAD is
provided in Figure 3. Naturally, these suggested
strategies will change with the emergence of
new  data,  and  it  is  conceivable  that  fewer
patients will have to undergo cardiac catheteri-
zation if CTA can identify patients who will not
benefit from revascularization. 
The coming years will likely see stress test-
ing  evolving  into  a  secondary  role  for  the
assessment  of  patients  with  suspected  CAD,
providing information on hemodynamic signif-
icance and ischemic burden in patients with
CAD  in  the  moderate-severe  range,  or  for
patients  not  eligible  for  CTA.  Clinically,  it  is
uncertain if ischemia testing provides informa-
tion  that  is  of  incremental  value  for  patient
management  over  anatomical  assessment
alone. For this purpose, clinical studies, such
as the ISCHEMIA study, need to disentangle the
information provided by stress testing that is
not directed towards the severity and location
of CAD, which is currently available from coro-
nary angiography. Looking forward, it is feasi-
ble that the integration of emerging CAD char-
Figure 3. Schema for a proposed algorithm of triaging patients with suspected but with-
out  known  coronary  artery  disease.  CAD,  coronary  artery  disease;  CTA,  computed
tomography angiography; tx, therapy.Review
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acteristics, e.g. plaque configuration and con-
sistency, shear stress analysis, and blood flow
dynamics,  will  evolve  into  a  comprehensive
coronary artery assessment, even though it will
likely require a substantial effort to clarify the
use  of  this  information  for  patient  manage-
ment and outcome. However, a comprehensive
coronary  artery  assessment  would  finally
enable us to move beyond simplistic categoriza-
tion of CAD for a more differentiated approach
to patients with coronary artery disease.71
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